Traumatic Encephalopathy Syndrome Criteria Poor for Predicting CTE
via HealthDayWEDNESDAY, May 20, 2026 -- Traumatic encephalopathy syndrome (TES) has poor performance for predicting chronic traumatic encephalopathy neuropathological change (CTE-NC), according to a study published online May 14 in Nature Medicine.
John D. Arena, M.D., from the University of Pennsylvania in Philadelphia, and colleagues reviewed antemortem clinical records for 1,038 cases in a neurodegenerative brain bank to examine the diagnostic accuracy of TES criteria for predicting CTE-NC. In all cases, neuropathological evaluation for CTE-NC was then conducted.
The researchers found that 25 cases (2.4 percent) met the criteria for TES diagnosis, six of which demonstrated CTE-NC (positive predictive value, 24.0 percent). CTE-NC was present in seven of the remaining 1,013 cases (0.69 percent). The diagnostic accuracy of TES for CTE-NC was due to exposure to repetitive head impacts as opposed to clinical features. No differences were seen in the prevalence of core or supportive clinical features of TES among CTE-NC cases versus a matched sample.
"Before we can responsibly diagnose CTE in living patients, we need a much clearer understanding of how the disease develops and which symptoms it truly causes," Arena said in a statement. "The necessary next step is prospective longitudinal research that follows people during life, carefully documents head injury exposures and symptoms, and then assesses for neuropathology after death."
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Source: HealthDay
Posted : 2026-05-21 03:09
Read more
- U.S. Hospitalizations for Heat-Related Illness Increasing
- 988 Hotline Leads to Fewer Suicides Among Young People, Study Finds
- Amputation Rates on the Rise for Opioid-, Non-Opioid-Related Hospitalizations
- Nearly Half of Women Misunderstand Breast Cancer Screening Guidelines
- Very Few Patients With HIV Report Using Long-Acting Injectable ART
- Super Shoes Might Increase Risk Of Running Injuries, Study Says
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions